Print Friendly, PDF & Email

NCT/Study#

NA /

21-109

A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)

DISEASE GROUP:

Neuro-Oncology

current phase:

Phase II

STUDY STATUS:

Active

Location:

Hackensack, NJ

For More information:

Call 201-518-3587